AMPRILAN 5MG PILLS

Active ingredient and dosage form

Amprilan pills:
1 pill contains Ramipril 1.25; 2.5; five; 10 mg;
30 pieces packaged.

Mechanism of action

Hypotensive, vasodilating, cardioprotective, natriuretic.

Indications and usage

Arterial hypertension; ronic heart failure; chronic heart failure after acute myocardial infarction in patients with stable hemodynamic parameters.

Dosage and administration

Amprilan is taken orally, regardless of the meal, with a large amount of liquid. The recommended initial dose of Amprilana is 2.5 mg 1 time per day (on an empty stomach, in the morning) or in 2 doses.

Adverse reactions

Since the cardiovascular system: reduction of blood pressure, orthostatic hypotension, orthostatic collapse, tachycardia, rarely - arrhythmia, angina, myocardial infarction.
On the part of the genitourinary system: the development or strengthening of symptoms of renal failure, proteinuria, decrease in urine volume, decreased libido.
CNS: cerebral ischemia, stroke, dizziness, headache, weakness, drowsiness, paresthesias, nervous irritability, anxiety, tremor, muscle spasm, mood disorders, when used in high doses - insomnia, anxiety, depression, confusion, fainting.
On the part of the senses: vestibular disorders, taste disorders (for example, “metallic” taste), smell, hearing and vision, tinnitus
On the part of the digestive system: nausea, vomiting, diarrhea or constipation, epigastric pain, intestinal obstruction, pancreatitis, hepatitis, cholestatic jaundice, abnormal liver function with the development of liver failure, dry mouth, thirst, decreased appetite, stomatitis, glossitis.

Contraindications

Hypersensitivity to ramipril and any other ingredient of Amprilan or other ACE inhibitors;
angioedema in history, including and associated with prior therapy with ACE inhibitors;
hemodynamically significant bilateral renal artery stenosis;
stenosis of the artery of a single kidney;
condition after kidney transplantation;
hemodialysis;
renal insufficiency (Cl creatinine <20 ml / min);
hemodynamically significant aortic or mitral stenosis (the risk of an excessive decrease in blood pressure, followed by impaired renal function);
hypertrophic obstructive cardiomyopathy;
primary hyper aldosteronism;
pregnancy;
lactation period;
age up to 18 years (efficacy and safety have not been established).

Special notes

Patients with hemodynamically significant stenosis of the aortic or mitral valve or any obstacle to outflow from the left ventricle should not use Amprilan.

Storage conditions

In a dry place, at a temperature not higher than 25 ° C.

Amprilan